First Targeted Kidney Disease Drug Approved by FDA

For people with IgA nephropathy, a progressive kidney disease affecting thousands worldwide, treatment options have been frustratingly limited for decades. That changed in late 2025 when the FDA approved sibeprenlimab, the first drug to actually target what causes the disease rather than just managing symptoms.

IgA nephropathy occurs when abnormal antibodies build up in the kidneys, eventually leading to kidney failure in many patients. Until now, doctors could only offer medications that slowed damage without addressing the underlying problem.

Sibeprenlimab works differently. The drug blocks a protein called APRIL that triggers the production of harmful antibodies in the first place, stopping the disease cascade before it starts.

"For the first time, we are actually trying to specifically address the underlying abnormality that drives IgAN," said lead investigator Dr. Vlado Perkovic from the University of New South Wales in Australia. The approval came after a phase 3 study of 510 patients showed the drug reduced protein in urine by 51.2% compared to placebo, a key marker of kidney damage.

Dr. Dana Rizk, a kidney specialist at the University of Alabama at Birmingham who helped lead the research, explained the shift in thinking. "We're realizing that the disease is not as benign as we once thought, so treating it promptly may be appropriate for a large number of patients," she said.

The safety profile looked promising too. No deaths occurred during the study, and side effects were mild to moderate, mostly upper respiratory infections similar to the common cold.

The Ripple Effect

This breakthrough is opening doors across kidney research. Several similar drugs are now in development, including zigakibart and atacicept, both showing early promise in phase 3 trials.

The broader impact extends beyond just one disease. These B-cell therapies represent a new approach to treating autoimmune conditions by intervening earlier in the disease process, potentially transforming care for other immune-related kidney problems.

Researchers are continuing to monitor patients to understand the long-term benefits and any potential risks. But for now, patients finally have reason for optimism after years of watching their kidney function slowly decline with few tools to fight back.

"People with IgAN should feel a sense of hope for the future," Dr. Perkovic said.